European Medicines Agency (EMA) approves safety label update for Novartis Beovu
- Novartis worked with the EMA to update the Beovu? (brolucizumab) label to guide physicians in their treatment of wet AMD ?
- The update includes the additional characterization of retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation1
- Novartis has established a multidisciplinary panel of internal experts collaborating with external advisors?to examine the root cause, potential risk factors and mitigation of these adverse events
- Novartis is confident that Beovu continues to represent an important treatment option for patients with wet AMD, with an overall favorable benefit/risk profile?
# # #
Novartis Media Relations E-mail:?media.relations@novartis.comPeter Zuest Novartis External Communications + 41 79 899 9812 (mobile) peter.zuest@novartis.com Eric Althoff Novartis US External Communications +1 646 438 4335 eric.althoff@novartis.com | Amy Wolf Novartis Division Communications + 41 61 696 58 94 (direct) + 41 79 576 07 23 (mobile) amy.wolf@novartis.com |